TMCnet News
MediWound's NexoBrid® and EscharEx® to be Highlighted in Multiple Presentations at the Symposium on Advanced Wound Care SpringYAVNE, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that seven presentations highlighting the positive clinical results from using NexoBrid® as an enzymatic debridement for severe burns and EscharEx for the debridement of chronic wounds will be presented during the Symposium on Advanced Wound Care Spring/Wound Healing Society Meeting (SAWC Spring), taking place April 5-9, 2017 in San Diego, California. “We are delighted with the depth and breadth of data to be presented at this year’s SAWC Spring in support of the effectiveness of EscharEx and NexoBrid in wound management and burn care, respectively. We are pleased to have the positive data from our EscharEx Phase 2 clinical trial presented as it demonstrates the important role this product can play in the treatment of chronic wounds. Debridement is a critical first step to facilitate wound management and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. It is thought that EscharEx could allow more patients to benefit from advanced wound healing and skin substitute products, which generally are not applied on wounds covered with eschar. We believe EscharEx can fill the long-standing unmet medical need for an effective and rapid nonsurgical debridement treatment for chronic wounds,” said Gal Cohen, President and Chief Executive Officer of MediWound. “The SAWC Spring meeting is a particularly good program as it brings together the entire interdisciplinary wound care team to learn more about advances in the field that will facilitate improved patient outcomes. We look forward to sharing our compelling data with these clinicians and to expanding the awareness of our proteolytic enzyme technologies as effective debridement treatments in severe burns and chronic wounds,” added Mr. Cohen. The following data highlighting NexoBrid and EscharEx will be presented during the SAWC Spring meeting:
About SAWC Spring/Wound Healing Society Meeting The Symposium on Advanced Wound Care/Wound Healing Society Meeting is the nation’s largest and most well-respected interdisciplinary wound care program within the clinical field. The Symposium on Advanced Wound Care Spring | Wound Healing Society meeting (SAWC Spring | WHS) serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists and dietitians — with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging research findings. About MediWound Ltd. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid®, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid® represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com. Cautionary Note Regarding Forward-Looking Statements
|